152 related articles for article (PubMed ID: 10335459)
21. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom.
UK Colorectal Cancer Screening Pilot Group
BMJ; 2004 Jul; 329(7458):133. PubMed ID: 15237087
[TBL] [Abstract][Full Text] [Related]
22. A case-control study to evaluate efficacy of screening for faecal occult blood.
Lazovich D; Weiss NS; Stevens NG; White E; McKnight B; Wagner EH
J Med Screen; 1995; 2(2):84-9. PubMed ID: 7497161
[TBL] [Abstract][Full Text] [Related]
23. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
Chen LS; Liao CS; Chang SH; Lai HC; Chen TH
J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564
[TBL] [Abstract][Full Text] [Related]
25. A comparison of tumour and host prognostic factors in screen-detected vs nonscreen-detected colorectal cancer: a contemporaneous study.
Mansouri D; McMillan DC; McIlveen E; Crighton EM; Morrison DS; Horgan PG
Colorectal Dis; 2016 Oct; 18(10):967-975. PubMed ID: 26859503
[TBL] [Abstract][Full Text] [Related]
26. Test, episode, and programme sensitivities of screening for colorectal cancer as a public health policy in Finland: experimental design.
Malila N; Oivanen T; Malminiemi O; Hakama M
BMJ; 2008 Nov; 337():a2261. PubMed ID: 19022840
[TBL] [Abstract][Full Text] [Related]
27. The positive predictive value of guaiac faecal occult blood test in relation to the number of positive squares in two consecutive rounds of colorectal cancer screening.
Manfredi S; Philip J; Campillo B; Piette C; Durand G; Riou F; Bretagne JF
Eur J Cancer Prev; 2011 Jul; 20(4):277-82. PubMed ID: 21633201
[TBL] [Abstract][Full Text] [Related]
28. Interval cancers in screening with fecal occult blood test for colorectal cancer.
Jensen BM; Kronborg O; Fenger C
Scand J Gastroenterol; 1992 Sep; 27(9):779-82. PubMed ID: 1411286
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of faecal occult blood tests requested outside the UK National Bowel Cancer Screening Programme.
McDonald R; Tomlins A; Smith S; Harmston C
J Clin Pathol; 2013 Apr; 66(4):330-4. PubMed ID: 23288919
[TBL] [Abstract][Full Text] [Related]
30. Screening for colorectal cancer using the faecal occult blood test, Hemoccult.
Hewitson P; Glasziou P; Irwig L; Towler B; Watson E
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD001216. PubMed ID: 17253456
[TBL] [Abstract][Full Text] [Related]
31. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma.
Tibble J; Sigthorsson G; Foster R; Sherwood R; Fagerhol M; Bjarnason I
Gut; 2001 Sep; 49(3):402-8. PubMed ID: 11511563
[TBL] [Abstract][Full Text] [Related]
32. The risks of screening: data from the Nottingham randomised controlled trial of faecal occult blood screening for colorectal cancer.
Robinson MH; Hardcastle JD; Moss SM; Amar SS; Chamberlain JO; Armitage NC; Scholefield JH; Mangham CM
Gut; 1999 Oct; 45(4):588-92. PubMed ID: 10486370
[TBL] [Abstract][Full Text] [Related]
33. Comparison of screen-detected and interval colorectal cancers in the Bowel Cancer Screening Programme.
Gill MD; Bramble MG; Rees CJ; Lee TJ; Bradburn DM; Mills SJ
Br J Cancer; 2012 Jul; 107(3):417-21. PubMed ID: 22782347
[TBL] [Abstract][Full Text] [Related]
34. Screen-detected colorectal cancers show improved cancer-specific survival when compared with cancers diagnosed via the 2-week suspected colorectal cancer referral guidelines.
Courtney ED; Chong D; Tighe R; Easterbrook JR; Stebbings WS; Hernon J
Colorectal Dis; 2013 Feb; 15(2):177-82. PubMed ID: 22709315
[TBL] [Abstract][Full Text] [Related]
35. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population.
Guittet L; Bouvier V; Mariotte N; Vallee JP; Arsène D; Boutreux S; Tichet J; Launoy G
Gut; 2007 Feb; 56(2):210-4. PubMed ID: 16891354
[TBL] [Abstract][Full Text] [Related]
36. Does the location of screen-detected cancers differ from that seen in the unscreened population?
Harmston C; Hunter J; Wong L
Colorectal Dis; 2010 Apr; 12(4):324-6. PubMed ID: 19341402
[TBL] [Abstract][Full Text] [Related]
37. [Repeat mass screening for fecal occult blood for the diagnosis of colorectal neoplasms in a rural district. Results of an informational campaign].
Hofbauer F; Mach K; Egermann G
Wien Klin Wochenschr; 1991; 103(10):288-95. PubMed ID: 1858377
[TBL] [Abstract][Full Text] [Related]
38. Tailored telephone counselling to increase participation of underusers in a population-based colorectal cancer-screening programme with faecal occult blood test: A randomized controlled trial.
Denis B; Broc G; Sauleau EA; Gendre I; Gana K; Perrin P
Rev Epidemiol Sante Publique; 2017 Feb; 65(1):17-28. PubMed ID: 28089385
[TBL] [Abstract][Full Text] [Related]
39. Estimating age group-dependent sensitivity and mean sojourn time in colorectal cancer screening.
Sung NY; Jun JK; Kim YN; Jung I; Park S; Kim GR; Nam CM
J Med Screen; 2019 Mar; 26(1):19-25. PubMed ID: 30261804
[TBL] [Abstract][Full Text] [Related]
40. Faecal occult blood screening and reduction of colorectal cancer mortality: a case-control study.
Faivre J; Tazi MA; El Mrini T; Lejeune C; Benhamiche AM; Dassonville F
Br J Cancer; 1999 Feb; 79(3-4):680-3. PubMed ID: 10027349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
